FORT WORTH, Texas, Jan. 13 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM), announced today that it is nearing the completion of its registration of CellerateRX in Mexico and has identified its first distributor in that country. Numerous physicians in the nation have already evaluated the Activated Collagen wound care product and were impressed with its speed and efficacy in the management of diabetic ulcers and are optimistic that it will play a tremendous role in the management of these types of wounds.
Demand for the product continues to grow in the middle-east as new orders are received; the product is also poised for distribution in South East Asia and South America upon completion of the necessary registrations. "The fact that international recognition for CellerateRX is increasing is very encouraging and reinforces what we have believed for a long time and that is that we have the best product in the market for the management of diabetic wounds," says Deborah Jenkins Hutchinson, President of Wound Management Technologies, Inc.
CellerateRX® is FDA cleared for acute and chronic wounds which include but are not limited to: diabetic ulcers, venous stasis ulcers, ulcers due to arterial insufficiency, pressure ulcers stages I-IV, surgical wounds, traumatic wounds, superficial wounds, and 1st and 2nd degree burns. It comes in two forms, a powder which is about 95% collagen, and a gel which is about 65% collagen, and contains no additives or synthetics. CellerateRX® is manufactured in the United States. "Several independently run evidence-based studies have certified our product's value, and the overwhelmingly positive data can now be accessed at www.woundmanagementtechnologies.com," said Cathy Bradshaw, President of Wound Care Innovations, the division that markets CellerateRX.
For Wound Management Technologies Shareholder Information please call 954-357-0614 or go to http://www.woundmanagementtechnologies.com
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), with its corporate headquarters in Fort Worth, Texas, and regional offices in Ft. Lauderdale, Florida is a rapidly growing provider of specialty medical products and advanced biotechnology solutions. The Company is following the lead of NASDAQ Biotech Stock INDEX leaders such as Celgene http://www.celgene.com, Geron http://www.geron.com, and Human Genome Sciences http://www.hgsi.com by working to leverage its existing technology and infrastructure to develop opportunities within the International Biotechnology and Genetic Engineering fields. WNDM also has an interest in Cancer Treatment. For more information on the Company please visit http://www.woundmanagementtechnologies.com
"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of 1995:
The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
SOURCE Wound Management Technologies, Inc.